Viking Therapeutics Inc. (NASDAQ:VKTX)

There are currently no videos for this stock.
To request coverage of this stock, please click the green request video box on the right.
Bands Volume 200 SMA 50 SMA 20 SMA Videos Alerts Articles Events
VKTX Weekly Chart

Old Forum Content for VKTX

Make a Forum Post
Become a member to view recent forum posts. Already a member? Sign in here.
Loading...
  • DavidK: @woodman $VKTX I agree with the guys viewpoints in This clip on long $VKTX and short the Dexcom
  • BarryC: I bot $VKTX....
  • Onthemark: @BarryC $VKTX Many of us are in and waiting for good things to come.
  • BarryC: @Onthemark $VKTX I know.... Just mentioning what I'm doing AS I do it... Its lookin pretty RIPE here.
  • champ: @BarryC $VKTX...is at $66...and I like your Entry posts...because it is always good to know what others are doing, I'm watch for beck-in Entry also. Good Luck!
  • champ: $VKTX...Entry at $65.13.
  • woodman: @Onthemark $VKTX - Flag here up around resistance area. We'll see how this resolves in the short term, but I'm confident it will present great updates on both its oral and subQ versions of VK2735 (obesity med) at Obesity Week in early November. Get your tickets for that train. https://obesityweek.org/
  • curtis: @BarryC $VKTX (long term hold. The last trial was a better outcome than $LLY). They also have a less effective oral in trial.I have limit order to buy more at $48. I have 1/2 position in this. A sept 20 Call is selling at 1.45-1.75, but have sold as high as 3.0)
  • BarryC: @curtis $VKTX $LLY Yeah, that's way over my head... The dumber the better for me, I only need/use the Chart :-)
  • woodman: @curtis $VKTX $LLY - VKTX has the best in class on tolerabilityfor any obesity drug in production or trials. And its weight loss %s are quite good. While other companies try to max out weigh loss without regard to tolerability, VKTX gives you both, and they don't hide their data like many other companies are with tolerability/safety. The obesity TAM is enormous and patients are going to want a drug they can stay on longer. VKTX is giving that, and ones that won't require as frequent applications. VKTX (or its acquirer) will command a very nice share of the TAM in time, plenty to make shareholders happy over the long haul.
  • rweis005: @champ $VKTX Can you share what your stop is
  • champ: @rweis005 $VKTX....For me, it is also about Market conditions....so my visual floating stop is around $64 to $63...because it also depends on what I think the Markets are going to do....because stocks are Not going to make a move higher, in a negative Market that is dropping and I will not let this stock fall down to $63, if the Markets keep sliding lower......
  • rweis005: @champ $VKTX Thanks, appreciate the insight
  • champ: @rweis005 $VKTX.....we just saw the first good sign, that for Now...that $64 $$$ price level held, so buyers are also watching. Good Luck!
  • woodman: $ARDX $VKTX $IOVA - biotechs working this morning.
  • MongosPawn: @woodman $ARDX $VKTX $IOVA Starter taken in $IOVA. Long the other two already. Perky.
  • Bs7518: @woodman $ARDX $VKTX $IOVA Added to $IOVA yesterday Long from below $ADRX $VKTK
  • woodman: @MongosPawn @Bs7518 $ARDX $VKTX $IOVA - Loving IOVA!
  • kenb: @woodman $ARDX $VKTX $IOVA Loving all 3 in my portfolio, bio-techs working well lately. Thanks.
  • joelsg1: @woodman $IOVA Similar to $VKTX on takeover potential.
  • woodman: @joelsg1 $IOVA $VKTX - I like that $IOVA has commercialized treatments and is being very aggressive pursuing treating doctors and hospitals.
  • woodman: $VKTX - https://finance.yahoo.com/video/viking-therapeutics-could-winner-glp-205037180.html
  • debeers: $VKTX-Insider sells 7,426,508.
  • Waylon: @debeers $VKTX Walletectomy?
  • woodman: @Henry $LLY - many are working on those. $VKTX is in phase 2 for its oral which, so far, has outstanding tolerability (along with efficacy). I think oral versions are what companies are looking for now, but also new iterations of obesity meds generally.
  • joelsg1: $VKTX Here we go again, sort of, bounced off round number $60 support and volume indicates short covering like yesterday. We still don't know a reason for yesterday's jump, but neither do nervous shorts. Long.
  • traderbren: @joelsg1 $VKTX - really got going when it cleared the VWAP.
  • joelsg1: @traderbren $VKTX Saw it before that, but yes, all technical types and algos watching the same things, which is why it's so hard to do the old in/out profitably.
  • Vineet: @joelsg1 $VKTX sold this weeks covered's at $70...my entry today at 63
  • Detailsart: $VKTX Big price jump last hour - Up $6.50 12% 6x normal hourly volume. Have not seen any new announcements/news since last Thursday.
  • Onthemark: @Detailsart $VKTX Institutions know something is going on.
  • Ben: $VKTX? The WOODMAN knows. ;-) Where yat, Woodman? Too busy with your HAPPY DANCE?
  • joelsg1: @Ben $VKTX Not Woodie, but long, likely either a leak of good data or perhaps a buyout offer. And keeps going so I laddered up Nov. call spreads.
  • DavidK: @joelsg1 $VKTX agree . I bought a few calls just to be involved . Up 23 % . Had more calls a few weeks or month ago but got out . Was tired of fooling with it and figured it would be some time for a catalyst. $MS has a 105 target
  • joelsg1: @DavidK $VKTX $LLY and $NVO flat, $GPCR and even $ALT up. I smell a buyout.
  • woodman: $VKTX - Replying to some posts... I was away today and didn't even see the move at first. I know as little as anyone else who is speculating on the reason for the jump today in VKTX (and, interestingly, some others including $ALT and $GPCR, as metion ...
  • joelsg1: $VKTX Added Nov. $60-70 call spreads. Supposedly, new data due on oral obesity pill during Obesity Week 11/3-6.
  • joelsg1: @joelsg1 $VKTX Dropped a bit since buy, so added same spreads out to 1/25 for same premium.
  • woodman: @joelsg1 $VKTX - I've been added back on the pullback from shares I sold up higher. Obesity Week should be a good showing for the company.
  • joelsg1: @woodman $VKTX Rev Shark pumping it today.
  • woodman: @joelsg1 $VKTX - MS apparently had some good stuff to say after meeting with CEO and CFO. They've had a $105 PT on it. (Others have higher PTs from June - $118-$125). I've been adding here and there since 8/2 up to today between $52 and $58. I missed the very lows down to $47 (8/5). I don't know what I was doing that I missed it that day.
  • jeffslm: @joelsg1 $VKTX - Thx for reminding of him. I'm going to sign up for his service for additional perspective.
  • champ: $VKTX now at $58.31...and this is Day-6 on this move, that was off of that low, $47.31, which was on 8/7...and is now up $11, since that low, which is almost $2 per day.... ....and Entry-timings is the only thing that really counts. ~~~~~~~~~~~~~~~~~~
  • PhilHarmonic: @Lou $ET $EPD $ARDX $HUMA $VKTX $BA $WFRD $DBRG #MuniBonds #biotechs Wishing you good luck and good health.
  • Bs7518: @woodman $VKTX $RHBBY $NVO #Roche as usual great summary thanks
  • Lou: I haven’t posted for some time as I don’t really have much to say that would be useful here. I’m holding and trading around a handful of stocks and a #MuniBonds ladder. In my self-managed account, I’m holding and trading ar ...
  • champ: @Lou $ET $EPD $ARDX $HUMA $VKTX $BA $WFRD $DBRG #MuniBonds #biotechs....Nice to hear from you...stay in touch. Take Care!
  • Lou: @Lou $ET $EPD $ARDX $HUMA $VKTX $BA $WFRD $DBRG #MuniBonds #biotechs How could I have forgotten my very large position, massively appreciated, $FTI.
  • sierramp: @Lou $ET $EPD $ARDX $HUMA $VKTX $BA $WFRD $DBRG #MuniBonds #biotechs Hi Lou, thanks for posting. Good to know what you are trading. Having a spouse in memory care must be incredibly hard on you. It's good to hear you have a lot of support from your family and staying active with the gym and training. Good to hear from you. Have a good weekend.
  • billyzeke: @Lou $ET $EPD $ARDX $HUMA $VKTX $BA $WFRD $DBRG #MuniBonds #biotechs Good to hear from you Lou, hang in there, and have a great weekend!
  • woodman: @Lou $ET $EPD $ARDX $HUMA $VKTX $BA $WFRD $DBRG #MuniBonds #biotechs - Thanks for the update and for checking in, Lou. Stay healthy, active, keep spending time with family, and live life as best/as much as you can.
  • joelsg1: @Lou $ET $EPD $ARDX $HUMA $VKTX $BA $WFRD $DBRG #MuniBonds #biotechs Best thoughts and wishes. Perhaps take a test drive in a Tesla Plaid S to literally lift spirits ;)
  • mhuie: @Lou $ET $EPD $ARDX $HUMA $VKTX $BA $WFRD $DBRG #MuniBonds #biotechs Take care, Lou Monica
  • woodman: $VKTX - I waited until the 2Q earnings/updates pop (to $71) subsided to add to this. I sold a little up there, but primarily just held, and I have been adding back and more in the low-mid $50s. Though the 200d is rising and not far off from price, I ...
  • sgiseller: @woodman $VKTX $RHBBY $NVO #Roche I am with you on $VKTX, I'm long and a bit underwater on stock, but have been selling weekly calls and doing rather well
  • woodman: $VKTX $RHBBY $NVO #Roche - One proviso is that I've yet to see evidence that the company is truy prepared to commercialize on its own. I believe it wants to be acquired. I think entering Phase 3 (for subQ) could move it closer to being acquired if an ...
  • sgiseller: @woodman $VKTX $RHBBY $NVO #Roche I believe they are totally short on facilities to mfg, not all that excited about the Nash drug, there have been many co's going after nash, seems like a niche ailment
  • woodman: @sgiseller $VKTX $RHBBY $NVO #Roche - I think management would like to off-load in some way the MASH/NASH so it can focus on obesity. Plus, obesity drugs may well work for MASH/NASH to some degree. If they don't find a way to off-load it, a company buying VKTX for obesity would get it essentially for free.
  • sierramp: @woodman $VKTX $RHBBY $NVO #Roche Thanks for your $VKTX analysis. I have a small spec position. I don't throw my money at the wall hoping something sticks. The risk / reward with $VKTX is better than many. Also stochastic cross, Wms percent R and the July PB.
  • PeterB: @woodman $VKTX $RHBBY $NVO #Roche VKTX was a learning opportunity for me. I went in too big intending it be a day trade and didn't get out. So I'm underwater and have decided to hold position and consider it a long term investment, but not adding at this point.
  • woodman: @PeterB $VKTX $RHBBY $NVO #Roche - Biotech is rough. I have only $VKTX $ARDX and $HUMA right now. The first two are holds (add and hold) for me. HUMA has its PDUFA likely tomorrow. If moves up nicely on an approval, I will sell a bunch the look to buy back after the inevitable move back down. If it is not approved ... look out below.
  • woodman: @Henry $LLY $NVO $VKTX - Heart, kidney, liver, sleep apnea, alcohol addiction, and on and on.
  • DavidG: @woodman $LLY $NVO $VKTX But the GLP1/GIP field is becoming crowded with new agents being introduced- some promising oral agents. I've been selling option premium on $VKTX rather than own the stock. It whips around so much that occ. you can time put/ BuPS sales.
  • woodman: @DavidG $LLY $NVO $VKTX - I hear you. Every bit of news, even when its sh-t news such as a company like Roche reporting only some data (what it deems favorable) while hiding other data (raising many questions), moves the other stocks. It's the Wild Wild West out there.
  • woodman: $VKTX may be stalling at descending resistance from 2/28. It is bull flaggish in one sense, but these are topping candles right at a resisance area. Not sure which way this will go, though my WAG (wild-ass guess) is lower/pullback. My crystal ball notoriously sucks, so take it all with a grain of salt. (I want to add to my VKTX for the fall Q3 reporting and Obesity Week in November, so I'd welcome a pullback.)
  • Bs7518: @woodman $VKTX I'll take your WAG anyday:)
  • woodman: @Bs7518 $VKTX - support levels: 60-61; 56-57.
  • DavidG: @woodman $VKTX I bought shares in mid-July, basis @ 56.5. When it blasted off 2 days ago, I sold 16Aug $70 covered calls on my entire position at $4.65 -- which is a lot of premium. If called away I'd make 24% on just the stock, so this seemed OK. I'm going to hold and let the call prem decay for a while. I'm also open to adding if it pulls back further.
  • bigreek42: bought some $vktx starter ready to add
  • RichardinME: @WhitePath $KRE $VKTX $NVDA Thanks to both you and Henry for your clarification. I'm sure it must be difficult to for Dan to do a video that caters to all types of investors. I'm long $NVDA but my cost is much higher just because I joined SMM at the ...
  • woodman: $VKTX trying to make a higher high from yesterday. I'm a long-termer and have been writing about this one for a long time. I remain long. This pop is nice, but I have longer term sites set. I will continue to add on pullbacks, as its prospects have gotten even better with its reporting this week. Great management is a key to biotech investing and VKTX has it. Bring on Obesity Week in November.
  • woodman: $VKTX higher high today.
  • curtis: @woodman $VKTX (still in red on this one). But, I believe there is room for this one to be a long term winner. This is a position, not a traded stock for me, in Long Term account.
  • woodman: @curtis $VKTX - If this gets into the 80s in the short term, I'll likely lighten up and look for a pullback to add back. At least that's my current thought. The only news I can think of between now and Oct. 3Q reporting/Nov. Obesity Week would be a surprise announcement of a partnership or buyout. Moving to Phase 3 subQ and to Phase 2 for oral are big deals. An acquirer might want in before these happen - to help develop a home-stretch Phase 3 trial plan for the subQ, but also the oral is really the bigger interest for BP CEOs. Everyone would like a pill. But who knows....
  • woodman: $LLY going down, at least in part, I think, because of $VKTX. Maybe when $VKTX pulls back, maybe $LLY will move back up. Holding $VKTX; watching $LLY on the sidelines.
  • kenb: @woodman $VKTX I'm pretty sure it was Guy Adami who mentioned their options. There was no discussion of their financial results, just the direct move to phase 3, that was the focus of the conversation. I also read somewhere that both $LLY and $NOVO went down on the news, so the market is treating them as a real contender. And as you pointed out, it could be sooner now.
  • woodman: @kenb $VKTX $LLY $NOVO - I saw Raymond James reiterate $300mm. I believe that figure comes straight from the CEO, Brian Lian. I listened to the conference call but had to leave my post for a while during it and missed a lot. That $300mm figure is for *two* trials and at least 4,500participants. Some posit as much as 2 to 2.5 years saved by going straight to Phase 3. That's is a double benefit. First, it shaves off a lot of cost up front. Second, it gets them to generating sales much earlier. That's huge when put together and goes a very long way toward paying for the acauisition should a company buy VKTX.
  • Henry: $VKTX GLP-1 drug is moving to Phase 3 and is knocking the stuffing out of $NVO & $LLY Sorry I did not see Woodman's earlier post
  • woodman: @Henry $VKTX $NVO $LLY - Here are some really inportant takeaways from yesterday's quarterly call:

    1. Straight to Phase 3, skipping Phase 2b altogether which everyone (including me) thought would be to Phase 2b. It's a wonderful surprise. As I just ...
  • woodman: $VKTX- I premise this by saying I know nothing, but I think 65-66 will be a short term top. It may recede from there. It will be interesting to see if this move creates a new floor.
  • kenb: @woodman $VKTX good call, it actually hit $65.18 this morning, and is backing off. Let's see what happens the rest of the day. Congrats on your prediction!
  • woodman: @kenb $VKTX - I don't feel the need to chase this, but I will add on future dips. I think Obesity Week in November will be a very big deal for VKTX. It will proudly show its stuff (including as of yet unseen data) and how it's better than all the competition on tolerability and at least as good if not better than the other upstarts on efficacy (and better than LLY/NVO), and will be able to provide more data. I think its pill will be a big deal. So, targeting what is next - a 3Q call in October, followed by Obesity Week in November. I figure perhaps a pullback after the euphoria we see today, then a ramp-up into those two events. A buyout would of course change everything, but that's far too specultive to judge. Note: My predictions are worth what you've paid for them.
  • kenb: @woodman $VKTX Liked "My predictions are worth what you've paid for them."
  • Detailsart: @woodman $VKTX Just want to thank you for bringing VKTX to my attention. Have been building a position in it.
  • woodman: @Detailsart $VKTX - we need to get to the finish line before thanks/congrats are in order. But I appreciate it. :-)
  • champ: $VKTX...HOD... appears to be picking-up momentum.
  • oldmaratom: @champ $VKTX #Do you look for this to go to $105.?
  • champ: @oldmaratom $VKTX #Do....Could...however there are a lot of traders in this stock, so don't really know how the zig-zags are going to effect the traders...becuse traders could trigger the investors to take some of their profits off.. at some point...... ....then after that, could get another leg......... ....so when a stock is up over 37%, have to expect that there will be some selling....and if that zig-zag triggers Investors, could have a reversal before it hits $90, is just one of many guesses. ~~ I'm only 1/2 size now, so I locked in 1/2 of my profits and Now..I'm going to see what happens...and I'm Trailing..with 2 profit.. safety-stops. Good Luck! ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
  • woodman: $VKTX - next resistance area around $80-82 if it doesn't stall out here. I'm enjoying this ride.
  • oldmaratom: @champ $VKTX #Do# Thanks champ, always appreciate you taking time to explain.Wishing you the very best.
  • woodman: $VKTX ends up closing just under my $65-$66 target. What happens tomorrow remains to be seen. Good stuff today, though. This is a buy the dips stock. I think November Obesity Week will be very good for VKTX.

    One more tidbit about its oral obesity ...
  • Henry: @RichardinME SMM is a challenge for long term investors who are also traders. Yes Dan will say he is holding NVDA in his long term accounts but then he tells us we shouldn't be in it. That works on your mind. He did say his trades haven't been working. There are some trades that have worked, $KRE, $VKTX today. I end up getting fixated on things I own, most of which are long term and end up doing nothing. For sure we are not in the market where the Mag 7 goes up everyday. I am really a great trader when the market is going up. It's correcting now, we have sector rotation. It is not a market where my trading skills shine. I say stay in your foxhole.
  • WhitePath: @Henry $KRE $VKTX

    Agree with Henry, there are time we can take a break and just watch. I am not finding much to trade with an unique edge and it is OK. No need to trade everyday.

    And to understand better what Dan is trying to say..... here are my ...
  • woodman: @DavidG $LLY $NVO - Thanks for the info and link. The same should apply for $VKTX's GIP obesity med - VK2735 https://vikingtherapeutics.com/pipeline/metabolic-disease-program/vk2735/ VKTX also has a separate NASH/MASH candiate - VK2809 - https://vik ...
  • Geewhiz: $VKTX Earnings and update perceived favorably. Up $7.32 after hours
  • woodman: @Geewhiz $VKTX - very surpring to me is that they are going to Phase 3 for subQ obesity med. That's big. Cuts off 9 months, probably. I truly thought they'd have to go Phase 2b first. I was wrong.
  • woodman: @woodman $VKTX - Lots of good stuff here: https://ir.vikingtherapeutics.com/2024-07-24-Viking-Therapeutics-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Corporate-Update HIghlights: •VK2735 to Advance to Phase 3 for Obesity; End-of-Phase 2 Meeting Planned for 2H24 •Oral VK2735 Phase 2 Study in Obesity Expected to Begin 4Q24 •Positive Biopsy Results From VK2809 Reported in June; End-of-Phase 2 Meeting in NASH/MASH Planned for 4Q24 •Enrollment Completed in Phase 1b Study of VK0214 for X-ALD; Data Expected 2H24 •In Vivo Data From Novel Amylin Agonist Program Reported at ADA in June; IND in Obesity Planned for 2025
  • woodman: $VKTX spiked up 25%, now back down to 20%. I wanted to sell some at 25% but wasn't fast enough.
  • kenb: @woodman $VKTX discussed on Fast Money tonight. It is estimated that they are going to need about $300 million to run and complete a phase 3 trial. A huge undertaking and amount of $'s for the company. They will need to either a secondary offering, partner up with an entity, or agree to be bought out by large pharma. The thought there was that they would be valued about $10 billion, which would equate to about $110 a share. That was their opinion, not mine. Only holding a small position.
  • woodman: @kenb $VKTX - Thanks. Do you recall who said that? Assuming that's an accurate figure (I don't know), did they mention that VKTX just reported that it has $942 million in cash compared to $342 million on 12/31/2023 which is plenty of money to see tha ...
Visit the Trading Forum to join in the discussion.
Stock Price $52.59
Change 1.86%
Volume 2,629,770

Viking Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company develops therapies for metabolic and endocrine disorders. It includes portfolio of five drug candidates in clinical trials or preclinical studies.

Request Video of VKTX
Already a member? Sign in here.
Past Month

Leading Peers

Past Month

Lagging Peers

Dan Fitzpatrick

Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:

  • Nightly video Strategy Sessions with a game plan for tomorrow
  • Got a stock you want Dan to look at? Just ask.
  • Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
  • Access to over 90,400 stock analysis videos
  • Access an ever expanding library (90,400) of educational videos that will save you time and make you money

Join a team of friends and traders that have one thing in common; a burning desire to succeed.

Become a Member Today!

Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...

Satisfaction Guaranteed!

Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!